芬吗通治疗异常子宫出血患者的有效性及不良反应分析  

Efficacy and Adverse Reaction Analysis of Finmoxone in Patients with Abnormal Uterine Bleeding

作　　者：杨栋霞[1] 马桂霞[1] YANG Dong-xia;MA Gui-xia(Zhengzhou First People＇s Hospital Gynecology,Henan Zhengzhou 450004,China)

机构地区：[1]郑州市第一人民医院妇科,河南郑州450004

出　　处：《药品评价》2018年第21期36-38,共3页Drug Evaluation

摘　　要：目的:探讨芬吗通治疗异常子宫出血患者的有效性及不良反应。方法:在郑州市第一人民医院2015年1月至2017年1月期间诊治的异常子宫出血患者中选取80例作研究对象,并按治疗方案不同分组:对照组(n=40)应用戊酸雌二醇片治疗,研究组(n=40)则应用芬吗通治疗,就两组患者的整体疗效与不良反应发生率进行统计学分析。结果:(1)研究组患者的整体治疗有效率是95.0%,高于对照组患者的77.5%(P<0.05);(2)研究组患者不良反应发生率是15.0%,低于对照组患者的35.0%(P<0.05)。结论:芬吗通治疗异常子宫出血患者的有效性、安全性均较高,值得推广应用。Objective To investigate the efficacy and adverse effects of fenmoxone in the treatment of abnormal uterine bleeding. Methods： 80 patients with abnormal uterine bleeding were selected for treatment between January 2015 and January 2017, and were treated in the control group （N=40） using estradiol valproate tablets, and in the study group （N=40） with Finmoxone treatment, and the overall efficacy and incidence of adverse reactions in two groups of patients were compared. Results： The overall treatment efficiency of 1 group was 95.00 %, which was higher than 77.50 % of control group patients （P〈0.05）; the incidence of ADR in the study group was 15.00 %, lower than 35.00 % in the control group （P〈0.05）. Conclusion： The efficacy and safety of fenmoxone in the treatment of abnormal uterine hemorrhage is higher, and it is worth popularizing and applying.

关 键 词：芬吗通 戊酸雌二醇片 异常子宫出血 不良反应 

分 类 号：R984[医药卫生—药品]